Feasibility and Tolerability of Ketogenic Interventions in Amyotrophic Lateral Sclerosis—A Dose-Finding Case Series.

Background/Objectives: Weight loss and hypermetabolism are negative prognostic factors in amyotrophic lateral sclerosis (ALS). Ketone bodies (β-hydroxybutyrate, βHB) as high-energy substrates may compensate for this energy deficit, since a ketogenic diet (KD) has been shown to increase survival and...

Descripción completa

Detalles Bibliográficos
Publicado en:Nutrients Vol. 18; no. 10; pp. 1628 - 1639
Autores principales: Herrmann, Christine, Satari, Samantha, Weber, Andrea, Ruschitzka, Tanja, Jagodzinski, Luisa, Elmas, Zeynep, Becker, Felicitas, Richter, Lars, Wiesenfarth, Maximilian, Michels, Sebastian, Weishaupt, Jochen H., Schuster, Joachim, Dorst, Johannes
Formato: research tables/charts Journal Article
Publicado: MDPI May2026
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=194141346&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 194141346
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        20726643
        B0TT
      jtl: Nutrients
      issn: 20726643
      maglogo: N
    pubinfo:
      dt: May2026
      vid: 18
      iid: 10
      pid: 97109
      pub: MDPI
    artinfo:
      ui:
        194141346
        194141346
        194141346
        10.3390/nu18101628
        194141346
      ppf: 1628
      ppct: 11
      formats:
      tig:
        atl: Feasibility and Tolerability of Ketogenic Interventions in Amyotrophic Lateral Sclerosis—A Dose-Finding Case Series.
      aug:
        au:
          Herrmann, Christine
          Satari, Samantha
          Weber, Andrea
          Ruschitzka, Tanja
          Jagodzinski, Luisa
          Elmas, Zeynep
          Becker, Felicitas
          Richter, Lars
          Wiesenfarth, Maximilian
          Michels, Sebastian
          Weishaupt, Jochen H.
          Schuster, Joachim
          Dorst, Johannes
        affil: Department of Neurology, University of Ulm, 89081 Ulm, Germany
      sug:
        subj:
          Amyotrophic Lateral Sclerosis Diet Therapy
          Diet, Ketogenic Methods
          Ketones Administration and Dosage
          Treatment Outcomes
          Human
          Male
          Female
          Germany
          Pilot Studies
          Prospective Studies
          Case Studies
          3-Hydroxybutyric Acid
          Enteral Nutrition
          Gastrointestinal Diseases Chemically Induced
          Patient Safety
          Sodium Chloride Administration and Dosage
          Carboxylic Acids Administration and Dosage
          Gastrostomy
          Energy Metabolism
          Body Weight
          Blood Glucose
          Hydrogen-Ion Concentration
          Dose-Response Relationship, Drug
          Questionnaires
          Descriptive Statistics
          Funding Source
          Male
          Female
      ab: Background/Objectives: Weight loss and hypermetabolism are negative prognostic factors in amyotrophic lateral sclerosis (ALS). Ketone bodies (β-hydroxybutyrate, βHB) as high-energy substrates may compensate for this energy deficit, since a ketogenic diet (KD) has been shown to increase survival and stabilize body weight in the SOD1 mouse model. In this case series, we tested exogenous ketone salts (KS), ketone esters (KE), and a KD, in patients with ALS and in healthy subjects to identify novel therapeutic interventions for subsequent clinical studies. Methods: KS (KetoForce® (KetoSports, Frisco, TX, USA)) were tested in healthy subjects (11.7 g and 15.6 g βHB) and patients (15.6 g βHB 3×/day over 3 days). KE (KE4® (KetoneAid, Falls Church, VA, USA)) containing 10.0 g βHB were applied in healthy subjects (once) and in patients (3×/day over 2 days). For the KD, KetoCal® 2.5:1 LQ MCT MF Vanilla (Nutricia, Frankfurt, Germany) was applied via percutaneous endoscopic gastrostomy over four weeks. Regular capillary βHB measurements were conducted, and adverse events were recorded. Results: Between January 2021 and March 2025, we treated nine patients with ALS and two healthy subjects at the Department of Neurology of Ulm University, Germany. KE and KS increased βHB temporarily. However, the elevation was more pronounced following KE (maximum 2.2–2.7 mmol/L vs. 0.8–1.2 mmol/L). The KD increased βHB levels continuously with nighttime fluctuations. No adverse events occurred under KE. KS caused diarrhea in 3/5 patients and 1/2 healthy subjects. The KD was well tolerated, with mild gastrointestinal symptoms occurring in all patients. Conclusions: All ketogenic approaches increased βHB blood levels. While the KD and KE provided good tolerability, KS caused significant gastrointestinal side effects. KD seems to be an interesting candidate for future clinical studies, as it prompted a long-term increase in βHB while providing satisfying tolerability. Since maintaining a KD long-term is difficult for oral-feeding patients, KE may constitute a feasible alternative.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N